LEVERAGE

Follow-On Funding From the National Institutes of Health for 2020 Cure Alzheimer's Fund Research Grants



(())

The emphasis on basic knowledge is absolutely critical. The tendency is to be driven by urgency which leads you to take any possible avenue, and that is a dangerous approach that leads to short-cuts, guesses, and applying investment dollars with no true underlying understanding. It also moves people away from the longterm research that is necessary.

-DAVID BALTIMORE, PH.D., NOBEL LAUREATE, NOBEL PRIZE FOR PHYSIOLOGY OR MEDICINE

66))

Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.

-ARCHIMEDES

OUR FOUNDING PRINCIPLES

The founders of Cure Alzheimer's Fund (CureAlz) embraced as a core tenet that the best way to accelerate potential therapies for Alzheimer's disease is to support fundamental proof-of-concept research into its causes. Established ideas and orthodox approaches to research attract funding within the traditional system. However, scientists with well-reasoned but unique or unconventional ideas regarding the contributing factors to Alzheimer's disease struggle to obtain the financing necessary to test their hypotheses. Cure Alzheimer's Fund takes bold, smart risks on promising early research, and the knowledge learned from these projects is shared with the entire field. Once validated through our grants, these ideas may receive follow-on funding from the National Institutes of Health / National Institute on Aging (NIH / NIA) and other institutions far beyond what our resources alone can provide.

A second and equally important tenet is the importance of advancing the entire field even though CureAlz can fund only a select group of investigators. CureAlz provides funding for research intended to be shared with and published to the scientific community and requires open communication and collaboration across its network of funded and affiliated researchers. As a result, every project returns benefits far beyond the advancement of just one lab or just one proprietary molecule. Similarly, the animal models commissioned by CureAlz are available to all scientific labs, not only to projects we fund.

The advantages achieved with substantial follow-on funding, science sharing, and collaboration are considerable. We thank our very generous donors who have made these investments possible and our researchers who have been truly remarkable and passionate leaders in the commitment to finding a cure for Alzheimer's disease.

\$14 million in CureAlz research in 2020 led to \$107 million from the National Institutes of Health.

7.6X

RETURN ON INVESTMENT FOR 2020

\$47 million for 2018-2020 yielded \$350 million in funding from the National Institutes of Health.

Our grants for proof-of-concept research provide the necessary data and derisking, leading to follow-on funding from the National Institutes of Health (NIH) / National Institute on Aging (NIA) and other investors. As an illustration of this strength, our 2020 research portfolio with distributions totaling \$14 million led to additional funding from the NIH / NIA of \$107 million, a return of 7.6X.

For the combined years of 2018 through 2020, the total of \$47 million in grants provided to researchers from Cure Alzheimer's Fund resulted in an extraordinary \$350 million of follow-on funding from NIH / NIA.

For the three years of 2018 through 2020 combined, the return of follow-on funding from the NIH / NIA is 7.5X.

CUREALZ GRANT INVESTMENTS AND RELATED NIH FUNDING TO CUREALZ SUPPORTED INVESTIGATORS

	CURE ALZHEIMER'S FUND TOTAL	NIH TOTAL					
FOUNDATIONAL RESEARCH							
GENETIC RISK FACTORS	\$1,897,500	\$7,538,244					
BIOMARKERS, DIAGNOSTICS, AND STUDIES OF RISK AND RESILIENCE	\$1,030,242	\$945,678					
BIOLOGICAL RESEARCH MATERIALS: NEW ANIMAL AND CELLULAR MODELS AND HUMAN SAMPLES	\$422,500	\$6,667,893					
EPIGENETIC FACTORS	\$1,437,375	\$37,740,163					
TRANSLATIONAL RESEARCH							
STUDIES OF NOVEL ALZHEIMER'S DISEASE GENES	\$924,781	\$0					
STUDIES OF AMYLOID PRECURSOR PROTEIN (APP) AND AMYLOID BETA	\$392,908	\$1,488,511					
STUDIES OF TAU	\$710,000	\$5,563,889					
STUDIES OF APOLIPOPROTEIN E (APOE)	\$1,720,421	\$18,775,050					
STUDIES OF THE IMMUNE RESPONSE IN ALZHEIMER'S DISEASE	\$1,767,500	\$6,621,628					
STUDIES OF ALTERNATIVE NEURODEGENERATIVE PATHWAYS	\$1,708,434	\$10,344,006					
DRUG DISCOVERY AND ENABLING TECHNOLOGIES							
DRUG SCREENING AND LEAD DRUG EVALUATION PROJECTS	\$1,492,999	\$3,607,872					
DRUG DELIVERY AND ENABLING TECHNOLOGIES	\$172,500	\$0					
PRECLINICAL AND CLINICAL DRUG DEVELOPMENT AND TRIALS							
PRECLINICAL DRUG DEVELOPMENT	\$259,366	\$6,622,270					
CLINICAL TRIALS	\$100,000	\$0					
CLINICAL TRIAL DESIGN	\$100,000	\$592,920					

	\$0 ¦	\$10MM	\$20MM	\$30MM	\$40MM
FOUNDATIONAL RESEARCH					
GENETIC RISK FACTORS					
BIOMARKERS, DIAGNOSTICS, AND STUDIES OF RISK AND RESILIENCE					
BIOLOGICAL RESEARCH MATERIALS: NEW ANIMAL AND CELLULAR MODELS AND HUMAN SAMPLES					
EPIGENETIC FACTORS					
TRANSLATIONAL RESEARCH					
STUDIES OF NOVEL ALZHEIMER'S DISEASE GENES					
STUDIES OF AMYLOID PRECURSOR PROTEIN (APP) AND AMYLOID BETA					
STUDIES OF TAU					
STUDIES OF APOLIPOPROTEIN E (APOE)					
STUDIES OF THE IMMUNE RESPONSE IN ALZHEIMER'S DISEASE					
STUDIES OF ALTERNATIVE NEURODEGENERATIVE PATHWAYS					
DRUG DISCOVERY AND ENABLING TECHNOLOGIES					
DRUG SCREENING AND LEAD DRUG EVALUATION PROJECTS					
DRUG DELIVERY AND ENABLING TECHNOLOGIES					
PRECLINICAL AND CLINICAL DRUG DEVELOPMENT AND TRIALS					
PRECLINICAL DRUG DEVELOPMENT					
CLINICAL TRIALS					
CLINICAL TRIAL DESIGN					



75 FUNDED INSTITUTIONS

675 Research projects 9990 PAPERS PUBLISHED


249

F U N D E D R E S E A R C H E R S 77,098

CITATIONS

\$160,000,000

As of December 2022





SUPPORT OUR RESEARCH

ONLINE

You can donate directly from our website—please visit: www.CureAlz.org/Giving/Donate.

MAIL

If you prefer to make a donation by personal check, please make your check payable to: Cure Alzheimer's Fund. Our address is: Cure Alzheimer's Fund, 34 Washington St., Suite 310, Wellesley Hills, MA 02481.

ΤΕΙΕΡΗΟΝΕ

If you would like to make a donation by telephone, please call us at 781-237-3800. Our business hours are 9 a.m. to 5 p.m. ET. When calling after hours, please leave a message and we will return your call the next business day.

DONOR ADVISED FUNDS

Donors with funds held by Fidelity Charitable, Schwab Charitable or Great Kansas Community Foundation may use the DAF Direct form on our website at www.CureAlz.org/giving/donate to process donations. For all other Donor Advised Fund holders, please mail checks to our office at: Cure Alzheimer's Fund, 34 Washington St., Suite 310, Wellesley Hills, MA 02481.

PLANNED GIVING

We offer a number of planned giving options, some of which may offer tax incentives. These include bequests, qualified charitable distributions (QCDs), charitable gift annuities, charitable remainder trusts (CRTs), charitable lead trusts (CLTs) and gifts of retirement assets or life insurance policies.

To explore these and other ways to give, please visit: www.CureAlz.org/Giving/Donate/ or contact Laurel Lyle at LLyle@CureAlz.org, or call 781-237-3800.



RECOGNIZED FOR EXCELLENCE



Charity Navigator awarded Cure Alzheimer's Fund its highest rating of four stars, and has listed the organization in the top three percent of all charities for ten consecutive years.



GuideStar lists Cure Alzheimer's Fund as a platinum-level participant—its highest level of recognition.



Cure Alzheimer's Fund is an accredited charity and meets all 20 of the Better Business Bureau's standards for charity accountability.

100% of all donations go to research



WWW.CUREALZ.ORG

34 Washington Street · Suite 310 · Wellesley Hills, Massachusetts 02481 · 781-237-3800

Cure Alzheimer's Fund is a "doing business as" name for the Alzheimer's Disease Research Foundation, a 501(c)(3) public charity with federal tax ID #52-239-6428